This is a working overview of angiotensin IV, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-17. Anything still debated is marked as such rather than presented as settled.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
=== Japan === Japanese food distribution drastically decreased from the effects of World War Two and the country's economic shortcomings. The need for food during the 1920s and 1930s rose drastically as Japan's population and average lifestyle increased. Japan was importing large amounts of rice, sugar, soybeans, and wheat from its colonies by 1935, and had a dependence on colonial possessions to distribute food to her people. 95% of Japanese rice between 1936 and 1938, just a few years before major conflict arose with the United States, was imported from its colonies in Korea and Formosa. Only 2% of Japan's rice came from foreign countries. As war engulfed Japan after 1941, food distribution efforts began to suffer. Japan lost a tremendous amount of cargo ships and was surrounded by an effective US blockade for most of the war. Imports were down, which cut off Japan from its primary source of food. Rationing programs, ran by Japan's Central Foodstuff Corporation and Local Foodstuff Corporations, were an attempt to distribute food equally among the general population. Changes in tax collection and price control were also created to feed Japan, but these measures ultimately did not supply the Japanese people with enough food for survival. The average ration allowance consisted of a flour mixture which was often unhealthy and barely edible. Normal consumers age 16 to 60 received an average 330 g of ration per day in May 1943, and the situation only became more desperate as the war progressed.
=== BOC (1968-2006) === BOC Group's purchase of Edwards in 1968 was followed by international expansion, particularly into Asia, and investment at the Crawley, Eastbourne, Shoreham and Burgess Hill sites. In 1984, Edwards developed and patented the first practical high vacuum dry (no-oil) pump. The design was taken up by the fast-growing semiconductor manufacturing market. In 1992, Edwards purchased Electrotech Ltd's semiconductor manufacturing exhaust gas management systems. It was based in Nailsea before moving to Clevedon, UK to add to Edwards' semiconductor manufacturing environmental abatement technology. Four years later in 1996, new facilities in Burgess Hill are inaugurated. In 1997, BOC merged its electronics gases business with Edwards as BOC Edwards. In the same year, the company purchased Systems Chemistry Inc, a supplier of management systems for ultrapure chemicals used in semiconductor manufacturing, from Submicron Systems Corp of Allentown (USA). It became Edwards' chemical management division. Allentown, USA. It became Edwards' chemical management division. In 1999, Edwards acquired the Minneapolis-based division of FSI International Inc, for US$38 million. This was followed by the purchase of the Hick Hargreaves vacuum ejector and deaerator units; Wilhelm Klein GmbH; Stokes piston pump operations, and Hibon Inc for £12.8 million from Smiths Group. In 2002, they purchased Seiko Industry's turbomolecular pump manufacturing business for £70 million.
with equality in the equilateral case. More strongly, Barrow's inequality states that if the interior bisectors of the angles at interior point P (namely, of ∠APB, ∠BPC, and ∠CPA) intersect the triangle's sides at U, V, and W, then
Rho factor A protein cofactor involved in signaling the termination of transcription in bacteria. Rho factor recognizes and binds a C-rich/G-poor terminator sequence in the nascent RNA transcript, which promotes dissociation of the transcriptional complex and release of the transcript from the DNA template. Other mechanisms of termination which do not require Rho factor also exist.
The true identity of the discoverers of carbon nanotubes is a subject of some controversy. A 2006 editorial written by Marc Monthioux and Vladimir Kuznetsov in the journal Carbon described the origin of the carbon nanotube. A large percentage of academic and popular literature attributes the discovery of hollow, nanometre-size tubes composed of graphitic carbon to Sumio Iijima of NEC in 1991. His paper initiated a flurry of excitement and could be credited with inspiring the study of many applications of carbon nanotubes. Though Iijima has been given much of the credit for discovering carbon nanotubes, it turns out that the timeline of carbon nanotubes goes back much further than 1991.
Sources: en.wikipedia.org
Russia attacked Kyiv with missiles and drones. Later in the day, at least nine people were killed and 29 others injured in a missile strike in Kryvyi Rih. Explosions were reported in Crimea and Krasnodar Krai according to local media. A Russian S-300 near Belbek airfield and two S-400s near Belbek and Sevastopol were destroyed according to Ukrainian officials. The US pledged another Patriot battery to Ukraine. Russia deployed S-500 batteries to Crimea, according to the HUR. A Ukrainian soldier claimed to have shot down a cruise missile using a machine gun, during a Russian air attack on Kyiv.
=== New Zealand === In New Zealand, a medical laboratory scientist must complete a bachelor's degree in medical laboratory science or biological or chemical science recognized by the Medical Sciences Council of New Zealand. As part of this degree they must complete clinical placement. Once they graduate they must have worked at least six months under supervision, be registered with the Medical Sciences Counsel of New Zealand, and hold a current Annual Practicing Certificate.
=== Asthma === The 2007 National Heart, Lung, and Blood Institute (NHLBI) asthma guidelines recommend against the use of non-selective beta blockers in asthmatics, while allowing for the use of cardio selective beta blockers. Cardio selective beta blocker (β1 blockers) can be prescribed at the least possible dose to those with mild to moderate respiratory symptoms. β2-agonists can somewhat mitigate β-blocker-induced bronchospasm where it exerts greater efficacy on reversing selective β-blocker-induced bronchospasm than the nonselective β-blocker-induced worsening asthma and/or COPD.
In a clinical trial, the rate of systolic orthostatic hypotension was 21% versus 9% with placebo and the rate of diastolic orthostatic hypotension was 12% versus 4% with placebo in people with Parkinson's disease taking the ODT form of selegiline. The risk of hypotension is greater at the start of treatment and in the elderly (3% vs. 0% with placebo). The rate of hypotension or orthostatic hypotension with the selegiline patch was 2.2% versus 0.5% with placebo in clinical trials of people with depression. Significant orthostatic blood pressure changes (≥10 mm Hg decrease) occurred in 9.8% versus 6.7% with placebo, but most of these cases were asymptomatic and heart rate was unchanged. The rates of other orthostatic hypotension-related side effects in this population were dizziness or vertigo 4.9% versus 3.1% with placebo and fainting 0.5% versus 0.0% with placebo. It is said that orthostatic hypotension is rarely seen with the selegiline transdermal patch compared to oral MAOIs. Caution is advised against rapidly rising after sitting or lying, especially after prolonged periods or at the start of treatment, as this can result in fainting. Falls are of particular concern in the elderly. MAOIs like selegiline may lower blood pressure by increasing dopamine levels and activating dopamine receptors, by increasing levels of the false neurotransmitter octopamine, and/or by other mechanisms. Meta-analyses published in the 1990s found that the addition of selegiline to levodopa increased mortality in people with Parkinson's disease.
This has resulted in an egg-shaped planet, likely to be destroyed within 400 million years. 14 August The World Health Organization (WHO) declares mpox a public health emergency of international concern for the second time in two years, following the spread of the virus in African countries. Human ageing is found to progress in two accelerated bursts from the ages of 44 and 60, rather than being a gradual and linear process. 16 August – The Planetary Habitability Laboratory publishes a report concluding that the Wow! signal was likely caused by a rare astrophysical event, the sudden brightening of a cold molecular cloud triggered by a stellar emission. 22 August – The first systematic analysis of 1,500 climate policy measures from 41 countries is published. Of the policy interventions that have been tried by 2022, it identifies 63 successful ones in terms of large trend breaks. The authors find that the introduction of a right combination of measures is crucial and that price-based instruments played a key role in these policy mixes. 23 August – BNT116, the world's first mRNA lung cancer vaccine, begins a Phase I clinical trial in seven countries. 29 August – The first global analysis estimating inadequate intakes of 15 micronutrients using dietary intake data is published, suggesting over half of the global population do not consume enough iodine (68%), vitamin E (67%), calcium (66%), iron (65%), riboflavin (55%), folate (54%), and vitamin C (53%).
Sources: en.wikipedia.org
Baritosis, a benign pneumoconiosis is associated with inhalation of dust containing barium sulfate or barium carbonate; the effects are reversible. Silver poisoning, like lithium poisoning, arises from misapplication of medications. A dramatic symptom of "argyria" is that the skin turns blue or bluish-grey. Thallium poisoning has been observed on several occasions, and it is well known that thallium compounds are highly toxic. Nonetheless, incidents of thallium poisoning are few. Tin poisoning from tin metal, its oxides, and its salts are "almost unknown"; on the other hand certain organotin compounds are almost as toxic as cyanide. Such organotin compounds were once widely used as anti-fouling agents.
The pharmacodynamics of AAS are unlike peptide hormones. Water-soluble peptide hormones cannot penetrate the fatty cell membrane and only indirectly affect the nucleus of target cells through their interaction with the cell's surface receptors. However, as fat-soluble hormones, AAS are membrane-permeable and influence the nucleus of cells by direct action. The pharmacodynamic action of AAS begin when the exogenous hormone penetrates the membrane of the target cell and binds to an androgen receptor (AR) located in the cytoplasm of that cell. From there, the compound hormone-receptor diffuses into the nucleus, where it either alters the expression of genes or activates processes that send signals to other parts of the cell. Different types of AAS bind to the AAR with different affinities, depending on their chemical structure. The effect of AAS on muscle mass is caused in at least two ways: first, they increase the production of proteins; second, they reduce recovery time by blocking the effects of stress hormone cortisol on muscle tissue, so that catabolism of muscle is greatly reduced. It has been hypothesized that this reduction in muscle breakdown may occur through AAS inhibiting the action of other steroid hormones called glucocorticoids that promote the breakdown of muscles. AAS also affect the number of cells that develop into fat-storage cells, by favouring cellular differentiation into muscle cells instead.
Automation: high throughput screening, LIMS, robotics. Protein/Peptide Chemistry: amino acid analysis, N- and C-terminal sequencing, peptide synthesis, peptide/protein arrays. Biophysics: calorimetry, CD, fluorescence, light scattering, SPR, ultracentrifugation. Flow Cytometry Fluorescence Activating Cell Sorting Protein Expression, Identification, and Profiling: differential fluorescence, conventional 2-D gel electrophoresis, disease biomarker discovery. Gene Expression and Profiling: gene arrays, real-time PCR. Mass Spectrometry: qualitative, quantitative, and structural analysis of proteins, carbohydrates, oligonucleotides, and lipids. Microscopy light microscopy and imaging, Confocal Microscopy Nucleic Acid Chemistry: DNA sequencing, DNA synthesis, RNA synthesis, genotyping. Separations: 1- and 2-D PAGE, capillary electrophoresis, chromatography. Quality Control: GLP, GMP, quality and compliance. Universal Proteomics Standard (UPS), a mixture of proteins used as reference standard in proteomics, introduced by the above-mentioned sPRG. This includes two sets: the original (UPS1, where all 48 proteins are at 48 pmol), and a dynamic range of concentrations (called UPS2), ranging from 500 amol to 50 pmol. Other: bioinformatics, carbohydrate analysis, differential display, recombinant protein production.
Known hypersensitivity to clomipramine, or any of the excipients or cross-sensitivity to tricyclic antidepressants of the dibenzazepine group Recent myocardial infarction Any degree of heart block or other cardiac arrhythmias Mania Severe liver disease Narrow angle glaucoma Untreated urinary retention It must not be given in combination or within 3 weeks before or after treatment with a monoamine oxidase inhibitor. (Moclobemide-included; however, clomipramine may be initiated sooner at 48 hours following discontinuation of moclobemide.)
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
The lyophilized powder is commonly kept at -20 °C or lower, protected from moisture and light. Solutions may require colder storage and should avoid repeated freeze-thaw cycles. General peptide stability practices apply.